• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Reata Pharmaceuticals Inc.

    8/7/23 5:21:58 PM ET
    $RETA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RETA alert in real time by email
    SC 13D 1 d497549dsc13d.htm SC 13D SC 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

     

     

    REATA PHARMACEUTICALS, INC.

    (Name of Issuer)

    Class A Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    75615P 103

    (CUSIP Number)

    Biogen Inc.

    225 Binney Street

    Cambridge, Massachusetts 02142

    (617) 679-2000

    Attention: Wendell Taylor, Assistant Secretary

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    July 28, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).

     

     

     


    SCHEDULE 13D

     

      1    

      NAMES OF REPORTING PERSONS

     

      Biogen Inc.

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      I.R.S. I.D. #33-0112644

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (see instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS* (see instructions)

     

      BK/WC

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

         7    

      SOLE VOTING POWER

     

      0

         8  

      SHARED VOTING POWER

     

      8,936,791(1)(3)

         9  

      SOLE DISPOSITIVE POWER

     

      0

       10  

      SHARED DISPOSITIVE POWER

     

      0

      11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      8,936,791(1)(3)

      12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* (see instructions)

     

      ☐

      13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      23.4%(2)

      14  

      TYPE OF REPORTING PERSON* (see instructions)

     

      CO


    (1)

    This amount includes (i) 4,046,291 shares of Class A common stock, par value $0.001 per share (the “Class A Shares”), (ii) 4,334,375 shares of Class B common stock, par value $0.001 per share, (the “Class B Shares” and, together with the Class A Shares, the “Reata Shares”), (iii) 70,808 Class A Shares that certain of the Relevant Stockholders (as defined below) have the right to acquire within 60 days upon exercise of options or restricted stock units (“RSUs”) granted to such Relevant Stockholders, of which options and RSUs to acquire 67,992 Class A Shares are currently exercisable and (iv) 485,317 Class B Shares that certain of the Relevant Stockholders have the right to acquire within 60 days upon exercise of options granted to such Relevant Stockholders, all of which options are currently exercisable. This amount assumes conversion of all Class B Shares held by certain of the Relevant Stockholders, or which certain of the Relevant Stockholders have the right to acquire, into Class A Shares on a one-for-one basis.

    (2)

    Calculation is based on the sum of 33,331,586 Class A Shares outstanding as of June 30, 2023, plus the Class A Shares that certain of the Relevant Stockholders have the right to acquire upon conversion of the Class B Shares they own or exercise of the options and RSUs such Relevant Stockholders hold. This percentage also assumes conversion of all Class B Shares held by certain of the Relevant Stockholders into Class A Shares on a one-for-one basis. Because each Class B Share is entitled to three votes per share, Biogen Inc. (“Biogen”) beneficially owns Reata Shares representing approximately 36.4% of the voting power of Reata Pharmaceuticals, Inc. (the “Issuer”) (assuming no conversion of Class B Shares and without taking into account options and RSUs granted to certain of the Relevant Stockholders).

    (3)

    The beneficial ownership of the Class A Shares is being reported hereunder solely as a result of the Support Agreements (as defined below).

    Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission by Biogen that it is the beneficial owner of any of the Class A Shares referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.


    Item 1. Security and Issuer.

    This statement on Schedule 13D relates to the Class A Shares of the Issuer. The principal executive office address of the Issuer is 5320 Legacy Drive, Plano, Texas 75024.

    Item 2. Identity and Background.

     

    (a)

    The name of the person filing this statement is Biogen Inc., a Delaware corporation.

     

    (b)

    The principal business address of Biogen is 225 Binney Street, Cambridge, Massachusetts 02142.

     

    (c)

    Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. Biogen has a broad portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy and co-developed two treatments to address a defining pathology of Alzheimer’s disease. Biogen is focused on advancing it’s pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases. Biogen supports its drug discovery and development efforts through internal research and development programs and external collaborations.

     

    (d)

    During the last five years, none of Biogen, the Issuer or the Relevant Stockholders (as defined below) have been convicted in a criminal proceeding of the type specified in Item 2(d) of Schedule 13D.

     

    (e)

    During the last five years, none of Biogen, the Issuer or the Relevant Stockholders have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)

    Not applicable.

    Item 3. Source and Amount of Funds or Other Consideration.

    The description of the Merger Agreement (as defined below) and the Support Agreements included below in response to Item 4 are incorporated by reference in this Item 3.

    Biogen expects to finance the Merger (as defined below) with a combination of cash on hand and term loan proceeds. In connection with entering into the Merger Agreement, Biogen has entered into a commitment letter, dated as of July 28, 2023, with JPMorgan Chase Bank, N.A. (“JPMorgan”), pursuant to which, subject to the terms and conditions set forth therein, JPMorgan has committed to provide a 364-day senior unsecured bridge loan facility in an aggregate principal amount of up to $1.5 billion, to fund a portion of the consideration for the Merger.

    The foregoing descriptions of the Merger Agreement and the Support Agreements are qualified in their entirety by reference to the full text of such agreements, copies of which are filed hereto as Exhibits 1 and 2-4, respectively, and are incorporated by reference in their entirety herein.

    Item 4. Purpose of Transaction.

    On July 28, 2023, Biogen, River Acquisition, Inc. (“Merger Sub”), a Delaware corporation and a wholly-owned subsidiary of Biogen, and the Issuer entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, and upon the terms and subject to the conditions set forth therein, Merger Sub will be merged with and into the Issuer (the “Merger”), with the Issuer surviving the Merger as a wholly-owned subsidiary of Biogen.

    Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each Class A Share issued and outstanding immediately prior to the Effective Time and each Class B Share issued and outstanding immediately prior to the Effective Time (in each case except for (i) Reata Shares owned by Biogen, Merger Sub or the Issuer, or by any direct or indirect wholly-owned subsidiary of Biogen, Merger Sub or the Issuer, in each case, immediately prior to the Effective Time; and (ii) any Reata Shares with respect to which statutory rights of appraisal have been properly and validly demanded) will be automatically canceled and converted into the right to receive $172.50 in cash, without interest and subject to any applicable withholding taxes.

     


    On July 28, 2023, concurrently with the execution of the Merger Agreement, Biogen and Merger Sub entered into a voting and support agreement (each, a “Support Agreement” and, together, the “Support Agreements”) with each of (i) J. Warren Huff, (ii) The 2021 JWH GRAT, (iii) R. Kent McGaughy, Jr., (iv) Lagos Trust, (v) Traweek Children’s Trust, (vi) CPMG, Inc., (vii) William E. Rose, (viii) Charles Henry Rose 2001 Trust, (ix) John William Rose 2022 Trust, (x) Montrose Investments I, L.P. (“Montrose LP”), (xi) Montrose Investments GP, LLC (“Montrose GP”), (xii) Evelyn P. Rose, (xiii) Evelyn P. Rose Fidelity SEP IRA, (xiv) Evelyn Potter Rose’s Survivor Trust, (xv) Charles E. Gale and (xvi) Charles E. Gale Fidelity Rollover IRA, (each a “Relevant Stockholder” and, collectively, the “Relevant Stockholders”), pursuant to which and subject to the conditions contained wherein, each Relevant Stockholder has agreed, among other things, to vote all of such Relevant Stockholder’s Reata Shares (a) in favor of the adoption of the Merger Agreement and any other matters necessary for the consummation of the Merger and other transactions contemplated thereby and (b) against any Acquisition Proposal (as defined in the Merger Agreement) or other transaction, proposal, agreement or action made in opposition to adoption of the Merger Agreement or in competition or inconsistent with the Merger or matters contemplated by the Merger Agreement.

    The Merger is expected to close in the fourth quarter of 2023. Upon completion of the Merger, the Issuer will become a privately held company and the Class A Shares will no longer be listed on any public market.

    The foregoing descriptions of the Merger Agreement and the Support Agreements are qualified in their entirety by reference to the full text of such agreements, copies of which are filed hereto as Exhibits 1 and 2-4, respectively, and are incorporated by reference in their entirety herein.

    Item 5. Interest in Securities of the Issuer.

     

    (a)-(b)

    The information set forth on the cover pages to this Schedule 13D are incorporated by reference into this Item 5.

     

    (c)

    Other than as described herein, Biogen has not effected any transaction in Class A Shares during the past sixty days.

     

    (d)

    Each of the Relevant Stockholders have the right to receive dividends from, and proceeds from the sale of, Class A Shares held of record and/or beneficially owned by each such Relevant Stockholder. In addition, the right to receive dividends from, and proceeds from the sale of, Class A Shares held of record and/or beneficially owned by Montrose LP, and Montrose GP is governed by their respective limited partnership agreements and limited liability regulations, as applicable, of each of such entities, and such dividends or proceeds may be distributed with respect to numerous general and limited partnership or membership interests.

     

    (e)

    Not applicable.

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 4 above summarizes certain provisions of the Merger Agreement and the Support Agreements and is incorporated herein by reference. The foregoing descriptions of the Merger Agreement and the Support Agreements are qualified in their entirety by reference to the full text of such agreements, copies of which are filed hereto as Exhibits 1 and 2-4, respectively, and are incorporated by reference in their entirety herein.

    Except as set forth herein, Biogen does not have any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.


    Item 7. Material to be Filed as Exhibits.

     

    Exhibit
    Number

      

    Description

    1    Agreement and Plan of Merger, dated July 28, 2023, by and among Biogen, Merger Sub and Issuer (incorporated by reference to Exhibit 2.1 to Biogen’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 31, 2023).
    2    Voting and Support Agreement, dated July 28, 2023, by and among Biogen, Merger Sub and each Relevant Stockholder set forth on Exhibit A thereto (incorporated by reference to Exhibit 10.1 to Biogen’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 31, 2023).
    3    Voting and Support Agreement, dated July 28, 2023, by and among Biogen, Merger Sub and each Relevant Stockholder set forth on Exhibit A thereto (incorporated by reference to Exhibit 10.2 to Biogen’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 31, 2023).
    4    Voting and Support Agreement, dated July 28, 2023, by and among Biogen, Merger Sub and each Relevant Stockholder set forth on Exhibit A thereto (incorporated by reference to Exhibit 10.3 to Biogen’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 31, 2023).


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: August 7, 2023

     

    BIOGEN INC.
    By:  

    /s/ Wendell Taylor

      Name: Wendell Taylor
      Title: Assistant Secretary
    Get the next $RETA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RETA

    DatePrice TargetRatingAnalyst
    7/6/2023$140.00Outperform
    TD Cowen
    6/12/2023$80.00 → $115.00Market Perform → Outperform
    SVB Securities
    10/19/2022$75.00Buy
    Guggenheim
    3/24/2022$91.00Buy
    Goldman
    3/1/2022$39.00 → $34.00Neutral
    Goldman Sachs
    12/9/2021$39.00Buy → Neutral
    Goldman Sachs
    12/9/2021$110.00 → $37.00Outperform → Neutral
    Robert W. Baird
    12/9/2021$112.00 → $68.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $RETA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Reata Pharmaceuticals with a new price target

      TD Cowen initiated coverage of Reata Pharmaceuticals with a rating of Outperform and set a new price target of $140.00

      7/6/23 7:38:38 AM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reata Pharmaceuticals upgraded by SVB Securities with a new price target

      SVB Securities upgraded Reata Pharmaceuticals from Market Perform to Outperform and set a new price target of $115.00 from $80.00 previously

      6/12/23 7:22:49 AM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Reata Pharmaceuticals with a new price target

      Guggenheim initiated coverage of Reata Pharmaceuticals with a rating of Buy and set a new price target of $75.00

      10/19/22 7:56:15 AM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RETA
    Financials

    Live finance-specific insights

    See more
    • Biogen Completes Acquisition of Reata Pharmaceuticals

      Reata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich's ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (NASDAQ:RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS® (omaveloxolone), as well as other clinical and preclinical pipeline programs. SKYCLARYS®, Reata Pharmaceuticals' lead asset, was approved for the treatment of

      9/26/23 8:59:54 AM ET
      $BIIB
      $RETA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Biogen to Acquire Reata Pharmaceuticals

      SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich's ataxia   Proposed acquisition represents meaningful step forward in Biogen's strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical needExpected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025Biogen to host investor conference call today at 9:00 a.m. ET. CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Reata Pharmaceuticals, Inc. (NASDAQ:RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to a

      7/28/23 7:05:44 AM ET
      $BIIB
      $RETA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development Programs

      SKYCLARYS® Approved by FDA in the U.S. Approximately 500 Patient Start Forms Received for SKYCLARYS Marketing Authorization Application for Omaveloxolone in Europe Under Review Announced $275 Million Debt Facility and Extended Cash Guidance Through the End of 2026 Focus on Neurology Pipeline; Announced Discontinuation of Bardoxolone CKD Programs Conference Call with Management on May 10, 2023, at 8:30 a.m. ET Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, today announced financial results for the first quarter

      5/10/23 6:40:00 AM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RETA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biogen Completes Acquisition of Reata Pharmaceuticals

      Reata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich's ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (NASDAQ:RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS® (omaveloxolone), as well as other clinical and preclinical pipeline programs. SKYCLARYS®, Reata Pharmaceuticals' lead asset, was approved for the treatment of

      9/26/23 8:59:54 AM ET
      $BIIB
      $RETA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.

      Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that at a special meeting held today, preliminary results indicate that the stockholders of the Company voted to approve the Company's previously announced acquisition (the "Merger") by Biogen Inc., a Delaware corporation ("Biogen"). Approximately 99.65 percent of the votes cast by the Company's Class A common stockholders and Class B common stockholders, voting as a single class, entitled to vote at the special meeting, voted to approve the Merger, which represen

      9/21/23 10:08:00 AM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifshitz Law PLLC Announces Investigations of EQRX, RVMD, NEWR, and RETA

      NEW YORK, Aug. 05, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EQRX to Revolution Medicines, Inc. Under the terms of the proposed merger, EQRX shareholders will receive the number of shares of Revolution Medicines, Inc. stock equal to the sum of ~7.69M Revolution Medicines, Inc. shares plus a number of shares equal to $870M divided by a price that is a 6% discount to the 5-day volume-weighted average Revolution Medicines Inc. share price measured in close proximity to the stockholder vote. If you are an EQRX investor, and would like additional information abo

      8/5/23 8:13:00 PM ET
      $EQRX
      $NEWR
      $RETA
      $RVMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Computer Software: Prepackaged Software
      Technology

    $RETA
    Leadership Updates

    Live Leadership Updates

    See more
    • Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer

      Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced the appointment of Rajiv Patni, M.D., as Executive Vice President, and Chief Research & Development Officer. Dr. Patni will report to Warren Huff, Chief Executive Officer, and will be responsible for overseeing the Company's research and development functions. "The team and I are excited to welcome Rajiv to Reata. His previous experience and his proven track record will help position the company for future growth," said Warren Huff, Chief Executive Officer. "His le

      6/13/23 6:45:00 AM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reata Announces the Appointment of Steven W. Ryder, M.D. to its Board of Directors

      Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced the appointment of Steven W. Ryder, M.D. to its Board of Directors, effective July 11, 2022. "We are thrilled to welcome Dr. Ryder to Reata's board," said Warren Huff, Reata's Chief Executive Officer. "He is joining us at a critical point in Reata's development with our New Drug Application under review with the U.S. Food and Drug Administration for omaveloxolone for the treatment of patients with Friedreich's ataxia. His knowledge will be invaluable to help us achieve our mission in developing innovative therapies that change patients' lives for the bett

      7/11/22 6:45:00 AM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RETA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for SKYCLARYS issued to REATA PHARMACEUTICALS INC

      Submission status for REATA PHARMACEUTICALS INC's drug SKYCLARYS (ORIG-1) with active ingredient OMAVELOXOLONE has changed to 'Approval' on 02/28/2023. Application Category: NDA, Application Number: 216718, Application Classification: Type 1 - New Molecular Entity

      2/28/23 5:14:09 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RETA
    SEC Filings

    See more
    • SEC Form 15-12G filed by Reata Pharmaceuticals Inc.

      15-12G - REATA PHARMACEUTICALS INC (0001358762) (Filer)

      10/6/23 4:07:57 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reata Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update

      8-K - REATA PHARMACEUTICALS INC (0001358762) (Filer)

      9/26/23 5:25:59 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POSASR filed by Reata Pharmaceuticals Inc.

      POSASR - REATA PHARMACEUTICALS INC (0001358762) (Filer)

      9/26/23 4:25:20 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RETA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Reata Pharmaceuticals Inc. (Amendment)

      SC 13D/A - REATA PHARMACEUTICALS INC (0001358762) (Subject)

      9/28/23 4:38:52 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Reata Pharmaceuticals Inc. (Amendment)

      SC 13D/A - REATA PHARMACEUTICALS INC (0001358762) (Subject)

      9/28/23 4:30:35 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Reata Pharmaceuticals Inc. (Amendment)

      SC 13D/A - REATA PHARMACEUTICALS INC (0001358762) (Subject)

      9/26/23 4:32:57 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RETA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Desai Antal Rohit returned 2,928,368 shares to the company (SEC Form 4)

      4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)

      9/28/23 4:32:06 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mcgaughy R Kent Jr returned 2,926,776 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)

      9/26/23 7:18:56 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wortley Michael D returned 49,701 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - REATA PHARMACEUTICALS INC (0001358762) (Issuer)

      9/26/23 4:30:47 PM ET
      $RETA
      Biotechnology: Pharmaceutical Preparations
      Health Care